SHILPAMED Shilpa Medicare Q4 FY25 results (Jan–Mar 2025) and concall
Shilpa Medicare reported strong financial results for Q4 and FY25, driven by growth in Formulation and Biologics segments, and significant debt reduction. The company is advancing a diverse product pipeline with several launches and filings anticipated in FY26. However, resolution of the USFDA import alert and delays in Albumin clinical trials remain areas to monitor.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 130 | 125 | 126 |
| EBITDA | 43 | 22 | 38 |
| Net profit | 30 | 16 | -6 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
